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Low Grade Papillary Adenocarcinoma of the 
Endolymphatic Sac, Papillary Adenoma of the 
Endolymphatic Sac. 
Note 
Endolymphatic sac tumors (ELSTs) are rare tumors of 
the petrous temporal bone. Classified as mastoid 
papillary tumors of unknown origin, these tumors were 
synthesized into a new, distinct clinico-pathological 
entity by Heffner in 1989. Initially described as a low 
grade papillary adenocarcinoma, their histologic 
appearance and apparent lack of metastatic potential 
has since persuaded most practitioners to reclassify 
them as papillary adenomas. ELSTs can arise 




The differential diagnosis for ELSTs includes all 
intrinsic temporal bone neoplasms (most commonly 
paraganglioma) as well as metastatic papillary thyroid 
carcinoma, metastatic renal cell carcinoma, and choroid 
plexus papilloma, the latter three of which are similar 
in appearance to ELSTs histologically. 
 
 
Clinics and pathology 
Disease 
Endolymphatic sac tumors are rare. As a recognized, 
distinct entity, ELSTs are relatively new.  
The first reported case of a tumor arising from the
endolymphatic sac was discovered during 
decompression of the endolymphatic sac for presumed 
unilateral Ménière's Disease in 1984. 
Although benign, ELSTs can be locally destructive. 
They present with hearing loss, tinnitus, facial nerve 
weakness or paralysis, vertigo, and can be lethal. CT 
imaging demonstrates erosion of the posterior petrous 
temporal bone with occasional intratumoral 
calcification. MRI tumor signal is isointense to brain 
and demonstrates gadolinium enhancement and 
heterogeneous signal intensity from intratumoral 
calcification and vascularity. 
Etiology 
The synthesis of sporadic temporal bone papillary 
tumors into a distinct clinicopathological entity was 
proposed in 1989 by Heffner, with the anatomic origin 
of these tumors being the endolymphatic sac. 
Knowledge of this tumor has grown, expedited in part 
by its association with VHL disease, yet many aspects 
are still poorly understood. 
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MRI T1 weighted axial images of the brain at the level of the endolymphatic sac and internal auditory canal. The top view without 
gadolinium contrast shows moderate expansion of the endolymphatic sac and duct on the right. The bottom view with gadolinium 
contrast shows contrast enhancement of the endolymphatic sac on the right. 
 
CT axial image of the temporal bones at the level of the endolymphatic sac and internal auditory canals. The vestibular aqueduct on the 
right is markedly widened directly behind the internal auditory canal and vestibule, in contrast to the appearance of the vestibular 
aqueduct on the left, which is thin and nondescript. The bony erosion and widening of the vestibular aqueduct on the right is highly 
suggestive of a neoplastic or otherwise destructive process within the endolymphatic sac, consistent with an ELST. 






Atlas Genet Cytogenet Oncol Haematol. 2010; 14(3)  323 
Initially described as a low grade papillary 
adenocarcinoma, the histologic appearance and 
apparent lack of metastatic potential of these tumors 
has convinced some to reclassify them as benign 
papillary adenomatous tumors. The high overall 
survival following surgical resection, despite locally 
aggressive behavior, is likely due to the underlying 
benign histology of the tumor. 
Epidemiology 
Over 175 case reports of ELSTs have now been 
reported in the literature. The majority of these ar  
single case reports of a practice group or university. 
As the majority of these case reports do not disclose the 
population size of their patient base, it is difficult to 
assess the true incidence of these tumors. ELSTs tend 
to afflict women more than men with an overall female 
to male ratio of 2:1 in a review of the literature. 
Clinics 
The most common presenting complaints were aural, 
with hearing loss occurring in neary every reported 
patient, followed by tinnitus, aural fullness, and 
imbalance. The symptoms of pulsatile tinnitus, otalgia, 
otorrhea, vertigo, and facial paresis were also present in 
some patients. Cranial neuropathies were also 
diagnosed either at the time of presentation or 
following treatment. The most commonly involved 
nerve was the facial nerve, with preoperative facial 
paresis or paralysis in 43% of patients. In patients wi h 
larger tumors or in those who delayed presentation for 
decades after onset of initial symptoms, multiple 
cranial neuropathies were present including trigeminal, 
glossopharyngeal, and vagal nerves. 
From a statistical standpoint, a vascular tumor eroding 
the temporal bone and cranial base is likely to be a 
paraganglioma, and likely a glomus jugulare  
tumor. Large glomus tumors as well as large ELSTs 
can both present as pink or purple masses encroaching 
on the middle ear and external auditory canal. Glomus 
tumors exhibit a characteristic "salt and pepper" tumor 
appearance on MRI, but this heterogeneity in signal 
reflects the vascularity of such tumors and is not 
pathognomonic. The heterogeneity in signal seen in 
large ELSTs - arising from hypervascularity as well as 
intra-tumoral hemorrhage and/or calcification - can 
often mimic glomus tumors in this respect. This is not
necessarily problematic, as management would proceed 
similarly for either histologic type of tumor: pre-
operative embolization followed by total tumor 
resection via the appropriate lateral skull base 
approach. 
Pathology 
ELSTs are highly vascular and are comprised of 
papillary cystic structures lined with a simple cuboidal 
or columnar epithelium. Siderophages and cholesterol 
clefts are seen, as are clear, vacuolated cells. Nuclear 
pleomorphism is not pronounced, and mitoses are rare.
Immunohistochemistry and special staining may aid in 
differentiation of papillary tumors of question-able 
origin. ELSTs usually stain positive for cytokeratin, 
vimentin, and epithelial membrane antigen, as well as 
stain on Periodic acid-Schiff (diastase sensitive). Some 
papers have also reported sensitivity to glial fibrillary 
acid protein; however, most authors have had poor 
tumor reactivity to glial fibrillary acid protein. Papillary 
thyroid metastasis to the temporal bone may be 
differentiated by positive reaction to thyroglobulin 
immunohisto-chemistry.  
Transthyretin has been shown to exhibit differential 
expression in choroid plexus papillomas with little o 
no expression in ELSTs. 
 
MRI T1 weighted images of the brain, showing a very large ELST of the left temporal bone, in axial view on the left and coronal view on 
the right. There has been complete erosion of the petrous temporal bone by the tumor, with significant brainstem and cerebellar 
compression. 
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Surgical resection is the primary modality of treatement 
for ELSTs. Despite the benign histologic nature of 
these tumors, complete resection appears crucial for 
ensuring success. Total tumor resection is clearly the 
treatment of choice, as only one patient with reported 
complete resection had subsequent recurrence. 
Although the most common presenting symptom was 
sensorineural hearing loss, many patients, particularly 
those with VHL disease, present with small ELSTs and
consequently present with serviceable hearing. VHL 
patients are unique in that all undergo active 
surveillance and cranial imaging for hemangioblastoma 
as part of their VHL disease management. 
Subsequently, ELSTs in these patients are frequently 
diagnosed early, with relatively little delay between 
onset of audio-vestibular symptoms and identification 
of tumor. This significantly affected surgical decision 
making, as 32% of patients underwent hearing 
conservation procedures while 68% underwent hearing 
ablative procedures. In patients with excellent 
preoperative hearing and a small ELST, such a hearing 
conservation approach may be warranted. However, th 
completeness of tumor resection should not be 
compromised for the sake of hearing conservation. Half 
of patients undergoing hearing conservation approaches 
with subtotal resection followed by adjuvant radiation 
therapy had regrowth of tumor. 
In some tumors, total resection cannot be achieved 
without risk of catastrophic loss of function or death, 
and in these patients subtotal resection may be 
warranted. Patients who have subtotal resection may
benefit from postoperative radiotherapy, but there still 
remains a roughly 50% risk of tumor regrowth and 
therefore close surveillance is warranted as re-resction 
may be necessary. Stereotactic radiotherapy has shown 
no increased benefit above standard fractionated 
radiotherapy in survival or recurrence rates, and 
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subtotal resection followed by stereotactic radiotherapy 
has uniformly resulted in tumor regrowth. There are no 
reported cases of radiation therapy and/or stereotactic 
radiotherapy used as the primary modality of treatment 
for ELSTs. 
Evolution 
There are currently no reported cases of spontaneous 
metastatic dissemination of ELSTs in the literature. 
Recently however, two reports have surfaced 
describing metastatic disease following subtotal 
resection. The first was a reported case of ELST drop 
metastasis with dissemination onto the ipsilateral 
cerebellar convexity beyond the original tumor sitein a 
patient who had undergone previous subtotal resection 
and radiotherapy. A second case of drop metastasis of 
ELST involved the spine, manifesting after multiple 
subtotal resections and three courses of stereotactic 
radiosurgery. 
These seminal reports serve to illustrate the importance 
of complete tumor removal on initial resection in order 
to minimize both recurrence and metastatic seeding. 
The oncologic principle of complete tumor extirpation 
on primary resection is certainly applicable to ELSTs, 
despite their benign histology and absence of 
spontaneous metastasis. 
Prognosis 
Overall survival characteristics for all reported cases of 
ELSTs are: 74% no evidence of disease, 20% alive 
with disease, and 4% died of disease, for the reporting 
periods. 
ELSTs are histologically benign yet sometimes 
destructive, highly aggressive lesions. They show 
excellent response to primary surgical resection, with 
or without adjuvant radiotherapy. Complete tumor 
removal on initial resection is crucial. Hearing 
preservation should not take precedence over complete 
tumor removal, as adjuvant radiotherapy does not 
ensure against tumor recurrence, which can be 
devastating and lethal. In addition, drop metastase 
following subtotal tumor resection have now been 
reported. In patients with VHL disease, regularly 
scheduled audiometry and surveillance MRI are vital to 
early detection of ELSTs, which can optimize the 
opportunity for hearing preservation without 
compromising tumor control. 
Genetics 
Note 
The current literature suggests that approximately one
third of all ELSTs are associated with VHL disease. 
VHL disease is an autosomal dominant familial cancer 
syndrome. VHL disease affects approximately 1 in 
39,000 people. It encompasses a variety of neoplasia 
both benign and malignant including renal cell 
carcinomas, central nervous system  
hemangioblastomas, retinal hemangioblas-tomas, 
pheochromocytomas, and cysts of the kidneys, 
pancreas, and epididymis. 
The gene responsible for VHL disease is a tumor 
suppressor and it has been mapped to chromosome 
3p25. The VHL gene product pVHL forms a multi-
protein complex that contains elongin B, elongin C, 
Cul-2, and Rbx1. 
The pVHL complex has a role in oxygen sensing. The 
VHL gene regulates vascular endothelial growth factor 
VEGF, and inactivation of the gene promotes VEGF 
overexpression and angiogenesis. In addition, its los of 
function mutation can increase expression of hypoxia-
inducible factor HIF1, stimulating angiogenesis and 
tumorigenesis. In VHL disease, it is believed that 
tumors arise when both an inherited germline mutation 
and a loss-of-function mutation of the wild-type VHL 
gene are present. 
In addition, it has been shown that somatic mutations t  
the VHL gene locus at 3p25/26 are detected even in 
cases of sporadic ELSTs, that is, in non-VHL patients. 
Genetic sequencing analysis of the 3p25 VHL gene 
locus in both sporadic and VHL-associated ELSTs 
demonstrates nucleotide substitution as well as 
deletion/frameshift errors. 
Even though temporal bone lesions were described in 
patients by Lindau in 1926, the association of these 
tumors with VHL disease was not made until recently. 
This clinical association has been confirmed at the 
molecular level with mutations in the VHL gene 
identified in endolymphatic sac tumors in VHL 
patients. Approximately 10% of patients with VHL 
disease have ELSTs, and approximately 30% of VHL 
patients with ELSTs have bilateral tumors. This 
variable phenotypic expression may be a reflection of 
VHL gene function secondary to the type of mutation 
present. 
Indeed, VHL disease has been found to have 
phenotypic expression consistent within members of a
family, thus implying a singular, conserved mutation 
within affected families. VHL disease is categorized 
into two familial types, with type 1 being without 
pheochromocytomas and type 2 being with 
pheochromocytomas. There is further subclassification 
of type 2 into type 2a, low risk for developing renal cell 
carcinoma, and type 2b, high risk for developing renal 
cell carcinoma. Clinical presentation type correlats 
with genetic mutation type: type 1 families usually 
have deletion or truncation mutations, whereas type 2 
families usually have missense mutations. 
If a family history of VHL disease exists, or if the 
diagnosis of VHL disease is made in the absence of an 
ELST, then early routine audiologic screening can 
allow for early tumor detection and the possibility of 
hearing preservation surgery should ELST develop. 
Positive identification of tumor on MRI with 
gadolinium is necessary prior to surgery: to date,  
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surgical exploration in VHL patients with 
audiovestibular symptoms but without MRI abnor-
mallities has not been documented and is not 
recommended. 




DNA / RNA 
The VHL gene is a tumor suppressor gene mapped to 
chromosome 3p25/26. 
Protein 
The VHL gene product, pVHL, forms a multi-protein 
complex that contains elongin B, elongin C, Cul-2, and 
Rbx1. 
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